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Toll-Like Receptor 9-Mediated Inflammation Triggers Alveolar Bone
Loss in Experimental Murine Periodontitis
Paul D. Kim,a,b Xia Xia-Juan,a Katie E. Crump,a Toshiharu Abe,c George Hajishengallis,c Sinem E. Sahingura,b
Department of Periodontics, School of Dentistry, Virginia Commonwealth University, Richmond, Virginia, USAa; Department of Microbiology and Immunology, School of
Medicine, Virginia Commonwealth University, Richmond, Virginia, USAb; Department of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia,
Pennsylvania, USAc
Chronic periodontitis is a local inflammatory disease induced by a dysbiotic microbiota and leading to destruction of the tooth-
supporting structures. Microbial nucleic acids are abundantly present in the periodontium, derived through release after phago-
cytic uptake of microbes and/or from biofilm-associated extracellular DNA. Binding of microbial DNA to its cognate receptors,
such as Toll-like receptor 9 (TLR9), can trigger inflammation. In this study, we utilized TLR9 knockout (TLR9/) mice and
wild-type (WT) controls in a murine model of Porphyromonas gingivalis-induced periodontitis and report the first in vivo evi-
dence that TLR9 signaling mediates the induction of periodontal bone loss. P. gingivalis-infectedWTmice exhibited signifi-
cantly increased bone loss compared to that in sham-infectedWTmice or P. gingivalis-infected TLR9/mice, which were resis-
tant to bone loss. Consistent with this, the expression levels of interleukin 6 (IL-6), tumor necrosis factor (TNF), and receptor-
activator of nuclear factor kappa B ligand (RANKL) were significantly elevated in the gingival tissues of the infectedWTmice but
not in infected TLR9/mice compared to their levels in controls. Ex vivo studies using splenocytes and bone marrow-derived
macrophages revealed significantly diminished cytokine production in TLR9/ cells relative to the cytokine production inWT
cells in response to P. gingivalis, thereby implicating TLR9 in inflammatory responses to this organism. Intriguingly, compared
to the cytokine production inWT cells, TLR9/ cells exhibited significantly decreased proinflammatory cytokine production
upon challenge with lipopolysaccharide (LPS) (TLR4 agonist) or Pam3Cys (TLR2 agonist), suggesting possible cross talk be-
tween TLR9, TLR4, and TLR2. Collectively, our results provide the first proof-of-concept evidence implicating TLR9-triggered
inflammation in periodontal disease pathogenesis, thereby identifying a new potential therapeutic target to control periodontal
inflammation.
Periodontitis is one of the most common inflammatory dis-eases worldwide, affecting more than 47% of the U.S. adult
population and leading to destruction of tooth-supporting struc-
tures (1). Although a dysbiotic biofilm structure initiates the dis-
ease, the periodontal tissue destruction occurs as a result of a dys-
regulated immune response to the microbial insult (2). Chronic,
persistent immune responses to this complex microbiome not
only can lead to tooth loss but also are associated with increased
risk for several systemic complications, including atherosclerosis,
diabetes, adverse pregnancy outcomes, pulmonary diseases, rheu-
matoid arthritis, and cancer (3–8). Periodontal research currently
focuses primarily on identifying disease biomarkers, understand-
ing mechanisms of pathogenesis, and identifying therapeutic tar-
gets to prevent the deleterious effects of periodontal inflammation
on both local and systemic tissues.
The host immune response is initiated upon sensing of mi-
crobe-associated molecular patterns (MAMPs) by families of re-
ceptors collectively called pattern recognition receptors (PRRs)
(9). The binding of MAMPs to PRRs promotes the release of in-
flammatory mediators that promote the induction of innate
immune mechanisms aiming to eliminate pathogens and also or-
chestrate the development of the adaptive immune response. Toll-
like receptors (TLRs) are themost widely studied PRRs that play a
critical role as the first line of defense againstmicrobial insults and
also serve as a bridge between innate and adaptive immunity. Sev-
eral types of cells can express TLRs, and each receptor is involved
in the sensing of distinctmicrobial products. TLRs that are located
on the plasmamembrane (TLR1, -2, -4, -5, -6, and -10) recognize
structural components of pathogens, such as proteins, lipopro-
teins, and polysaccharides. The receptors that reside in the endo-
somes (TLR3, -7, -8, and -9) are specific for nucleic acids, includ-
ing microbial or self RNA and DNA (9). TLRs are type I
transmembrane proteins composed of an extracellular leucine-
rich repeat (LRR) domain that is involved in ligand recognition, a
transmembrane domain, and a Toll-interleukin 1 (IL-1) receptor
(TIR) domain that is involved in signaling. The signaling path-
ways activated by TLRs engage adaptor molecules that are re-
cruited by TIR/TIR domain interactions and include myeloid
differentiation primary response 88 (MyD88), TIR domain-con-
taining adaptor protein (TIRAP, also known as MAL for MyD88
adaptor-like), TIR domain-containing adaptor inducing inter-
feron (IFN) (TRIF), and TRIF-related adaptormolecule (TRAM).
MyD88 is essential for signaling through all TLRs except TLR3
and is involved in early nuclear factor-B (NF-B) and mitogen-
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activated protein kinase (MAPK) activation and proinflammatory
gene expression. Although the innate immune response, includ-
ing TLR-mediated inflammatory responses, is potentially protec-
tive against infectious challenge, excessive or dysregulated activa-
tion of these sensors may lead to persistent, chronic inflammation
inmany conditions, including periodontal disease. Hence, a thor-
ough understanding of the molecular mechanisms involved in
TLR activation is considered to be crucial in the development of
therapeutics in several diseases, including periodontitis (10, 11).
Nucleic acids represent one of the key components that are
sensed by the innate immune system (12). During infection, DNA
andRNA that are sequesteredwithin bacteria, viruses, or host cells
can be released and subsequently detected by specific receptors,
activating inflammatory signaling cascades (13). Toll like receptor
9 (TLR9) is themajor sensor formicrobial unmethylated/hypom-
ethylated CpG (cytosine-phosphate-guanosine) DNA motifs. It
activates nuclear factor kappa B (NF-B), activator protein 1 (AP-
1), and mitogen-activated protein (MAP) kinase signaling path-
ways, which stimulate proinflammatory activities, but also the
IFN regulatory factor (IRF) pathway, which can induce type I
interferon and anti-inflammatory activities (9). Periodontal tis-
sues are constantly exposed tomicrobes, and tissue homeostasis is
mediated by a balance between continual turnover of microbial
and host cells. The premise of this study was that the constant cell
turnover provides a platform for the continuous presence of nu-
cleic acids in the periodontium which could thereby exacerbate
inflammatory responses through recognition by TLR9. Despite
having been fairly well studied in relation to various diseases of
infectious or immunological origin, the role of nucleic acid sens-
ing by intracellular PRRs in the pathogenesis of periodontitis has
received little attention. Previous clinical studies from our group
and others have demonstrated increased TLR9 gene and protein
expression in gingival tissues associated with chronic periodonti-
tis (14–16). TLR9 showed the highest gene expression among all
innate receptors, and the increased expressionwas predominantly
localized in the connective tissue and basal epithelial layers (14). It
is also well established that the host genetic background affects
susceptibility to periodontitis (17). Recently, both our group and
others revealed differential expression of specific single-nucleo-
tide polymorphisms (SNPs) in the TLR9 gene in individuals with
chronic periodontitis, providing further evidence for the involve-
ment of TLR9 in periodontal disease (18, 19). Additionally, in
vitro investigations demonstrated that periodontitis-associated
bacterial DNA upregulates several genes of the innate immune
response and induces the production of proinflammatory cyto-
kines through TLR9 in macrophages and epithelial cells (20–22).
In fact, a recent study has identified the TLR9 gene as one of the
most promising candidate genes involved in the pathogenesis of
periodontitis by using an integrative gene prioritization method
(23). Collectively, emerging evidence suggests that TLR9-trig-
gered immune responses may constitute a novel inflammatory
pathway in periodontitis (24).
The importance of specific PRRs in mediating pathological in-
flammation requires the use of in vivo models, which, unlike in
vitro models, can replicate the complexity of the interactions be-
tween the immune response, the microbiome, and the host tissue
(25). One of the most widely used in vivomodels of periodontitis
involves inoculation of the murine oral cavity with Porphyromo-
nas gingivalis by oral gavage (25–27). P. gingivalis is a keystone
pathogen in periodontitis and orchestrates inflammatory bone
loss upon its colonization of themurine oral cavity (2). As alluded
to above, we hypothesize that TLR9 activation contributes to the
pathogenesis of periodontitis by promoting enhanced inflamma-
tion. To test this hypothesis, we utilized the oral gavage model
with P. gingivalis and TLR9 knockout (KO) mice to characterize
the role of TLR9 in periodontal disease pathogenesis. We further
determined whether lack of TLR9 signaling affects inflammatory
responses to P. gingivalis and various TLR ligands by using ex vivo
models. To our knowledge, this is the first in vivo study to inves-
tigate the role of an intracellular nucleic acid sensor in the patho-
genesis of periodontitis.
MATERIALS AND METHODS
Bacteria. P. gingivalis (strain ATCC 33277) was grown in an anaerobic
chamber using brain heart infusion (BHI) broth (Difco Laboratories)
supplemented with 0.5% yeast extract, 5g/ml hemin, 0.5g/ml vitamin
K, and 0.1% cysteine as described previously (20).
Mice. All the experiments involving studies with animals have been
approved by the institutional animal care and use committee at Virginia
Commonwealth University. TLR9/ mice with the periodontitis-sus-
ceptible BALB/c background were obtained from Denis Klinmann (Na-
tional Cancer Institute, Bethesda, MD) with the permission of Shizuo
Akira (Osaka University). BALB/c wild-type (WT) mice were purchased
from Jackson Laboratory (Bar Harbor, ME). All the animals were housed
in a sterile, specific-pathogen-free room in individually ventilated cages.
Age- and gender-matched groups of wild-type and knockout animals
were used for each experiment.
P. gingivalis-induced murine periodontitis model. Periodontal in-
flammation and bone loss were induced by oral inoculation with P. gin-
givalis following published protocols (27). Briefly, the mice were given
kanamycin in drinking water (1 g/liter) for 7 days, followed by a 5-day
antibiotic-free period. The mice were then infected with 2 109 CFU of
live P. gingivalis (ATCC 33277) in 100 ml of vehicle comprised of phos-
phate-buffered saline (PBS) containing 2% carboxymethyl-cellulose
(CMC) that was placed into the esophagus and oral cavity. The inocula-
tions were performed three times within 48 h at the first and the second
week (a total of 6 inoculations). Control mice from each group (wild type
and knockout) received the antibiotic pretreatment and the CMC gavage
without P. gingivalis. Seven weeks after the first gavage, the mice were
euthanized by CO2 inhalation and cervical dislocation.
Oral microflora analysis. The levels of P. gingivalis colonization were
assessed using quantitative real-time PCR (qPCR) of the ISPg1 gene (P.
gingivalis) (28). Briefly, bacterial samples were collected by paper point
from the uppermolars and incubated in BHI (Difco laboratories) supple-
mented with 0.5% yeast extract, 5g/ml hemin, 0.5g/ml vitamin K, and
0.1% cysteine anaerobically for 1 week (29, 30). The suspension was cen-
trifuged, and thebacterial pelletwaswashedwithPBS followedby isolationof
genomic DNA (gDNA) using the DNeasy kit (Qiagen, Valencia, CA). qPCR
wasperformedwith theAppliedBiosystems7500 fast systemusingRT2SYBR
green ROX qPCR master mix (Qiagen) and the following primers (IDT):
ISPg1 (P. gingivalis): 5=-CGCAGACGACAGAGAAGACA-3= and 5=-ACG
GACAACCTGTTTTTGATAATCCT-3=. A standard curve was obtained
using 5-fold serial dilutions of 1 106 P. gingivalis DNA.
P. gingivalis antibody levels. Blood samples were collected from each
mouse strain before inoculation of bacteria and at the time of euthanasia
at week 7 using cheek bleed or cardiac puncture, respectively. Sera were
analyzed for P. gingivalis-specific-antibody levels using enzyme-linked
immunosorbent assays (ELISAs) (31). Briefly, the wells of the 96-well
plates (Costar; Fisher Scientific) were coated with formalin-fixed P. gingi-
valis (1  108/well) at 4°C overnight. The plates were washed using PBS
with 0.05%Tween 20 (PBST) (wash buffer). To prevent nonspecific bind-
ing, plates were blocked with 1% bovine serum albumin (BSA) in PBS for
30 min at room temperature. The serum samples were added into each
well and incubated for 2 h at 37°C. Serial dilutions of unlabeledmouse IgG
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(Southern Biotech) served as the standard. Following another wash step,
P. gingivalis-specific IgG was incubated with horseradish peroxidase
(HRP) conjugated to secondary antibody (goat anti-mouse IgG; Southern
Biotech) for 1 h at 37°C. ELISA wells were color developed with 3,3=,5=5=-
tetramethylbenzidine (TMB; SouthernBiotech) for 20 min at room tem-
perature, and the enzyme reaction was stopped by adding 0.1 N H2SO4.
The plates were read at 450 nm.
Determination of periodontal bone loss. Alveolar bone loss around
the maxillary molars was determined using microscopy as described pre-
viously (32). Briefly, at the end of each experiment, the animals were
sacrificed, followed by defleshing of the skulls by autoclaving. The speci-
mens were then immersed in 3% hydrogen peroxide overnight and
stained with 1% methylene blue. The distance from the cemento-enamel
junction (CEJ) to the alveolar bone crest (ABC) wasmeasured at a total of
14 predetermined buccal sites per mouse using a stereoscopic zoom mi-
croscope (SMZ1000; Nikon) at amagnification of40. To calculate bone
loss, the 14-site total CEJ-ABC distance for each mouse was subtracted
from themeanCEJ-ABCdistance of sham-infectedmice. The results were
expressed in millimeters, and negative values indicated bone loss relative
to the results for sham controls. The specimens were imaged using a desk-
topmicro-CT (computed tomography) system (Brüker Skyscan 1173mi-
cro-CT scanner; Skyscan NV, Kontich, Belgium) at a resolution of 1,120
by 1,120 pixels in all three spatial dimensions by setting the sagittal plane
parallel to the X-ray beam axis.
Determinationof inflammatorymediator expression ingingival tis-
sues. The gingival tissues were harvested from around the maxillary mo-
lars at the time of euthanasia, and total RNA was isolated and cDNA was
generated as described previously (14). The levels of IL-6, tumor necrosis
factor (TNF), and receptor-activator of NF-B ligand (RANKL) expres-
sion in gingival tissues of the mice in each group were determined by
real-time PCR (Applied Biosystems 7500) using SYBR green master mix
(SaBiosciences) and the following specific primer sets: for RANKL, for-
ward, 5= CAG CAT CGC TCT GTT CCT GTA 3=, and reverse, 5= CTG
CGT TTT CAT GGA GTC TCA 3=; for IL-6, forward, 5= TCT ATA CCA
CTT CAC AAG TCG GA 3=, and reverse, 5= GAA TTG CCA TTG CAC
AACTCTTT3=; for TNF, forward, 5=CTGAACTTCGGGGTGATCGG
3=, and reverse, 5= GGCTTG TCA CTC GAA TTT TGA GA 3=; and for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward, 5= AGG
TCG GTG TGA ACG GAT TTG 3=, and reverse, 5= GGG GTC GTT GAT
GGC AAC A 3=. The GAPDH gene was used as an internal control. The
relative amount of each mRNA was calculated using the cycle threshold
(2CT) method, where CT (CTmRNA CTGAPDH).
Spleen harvesting and processing. Uninfected naive mice (WT and
TLR9/) were sacrificed, and spleens were removed, segmented, and
placed in 10 ml serum-free RPMI 1640 medium (Invitrogen). Cells were
dispersed through a 40-m cell strainer and centrifuged at 1,500 rpm for
5min. The pellet was suspended in 5ml ACK lysis buffer (Quality Biolog-
ical, Inc.) for 5 min to allow for the lysis of red blood cells. Serum-free
medium was added to halt lysis, and the supernatant was collected and
centrifuged at 1,500 rpm for 5 min to pellet the leukocytes. The total
number of splenocytes was calculated by trypan blue exclusion assay, and
further experiments were performed. The cells (2  106 cells/well) were
cultured in RPMI 1640 medium (Invitrogen) supplemented with 2 mM
L-glutamine, 10% fetal bovine serum (Invitrogen), 50 M 2-mercapto-
ethanol, and 1%antibiotics (penicillin-streptomycin) at 37°C in a humid-
ified chamber in the presence of 5% CO2 using 48-well culture plates for
stimulation experiments.
Purification of bone marrow-derived macrophages. Bone marrow-
derived macrophages were propagated and purified following the meth-
ods of previously published studies (33). Briefly, bone marrow was ob-
tained from the femurs and tibias of 8-to-12-week-old wild-type and
TLR9/ mice. Red blood cells were osmotically lysed using ACK lysis
buffer. Following lysis, cells were washed and filtered through a 70-M
nylon mesh filter to remove debris. Bone marrow cells were resuspended
in bone marrow growth medium (BMM) (DMEM containing 4.5 g/liter
glucose, 100 mg/liter sodium pyruvate, 10% fetal calf serum, glutamine,
5  105 M beta-mercaptoethanol, and 10% supernatant from colony-
stimulating factor 1 (CSF-1)-transfected NIH 3T3 cells (courtesy of Mar-
lenaWestcott, Department ofMicrobiology and Immunology,Wake For-
est School ofMedicine). Cells were seeded at a density of 4 106 cells in 10
ml medium in a 125- by 50-mm Lab-Tek non-tissue culture-treated petri
dish and fed on day 3 by gently adding an additional 10 ml of BMM. On
day 6, the monolayer of macrophages was washed by aspirating the me-
dium and gently adding PBS to remove any nonadherent or dead cells.
Adherent macrophages were harvested by adding PBS to the monolayer,
incubating at 4°C for 10 min, and gently pipetting to remove cells. Mac-
rophages were further purified by CD11c-negative selection using mag-
netic bead isolation (Miltenyi Biotec) according to the manufacturer’s
protocol. Purifiedmacrophages were seeded at a concentration of 4 105
cells in 160 l of BMM without CSF-1-containing supernatant in a 48-
well plate for 12 to 18 h prior to stimulation.
Stimulationof splenocytes andbonemarrow-derivedmacrophages.
Heat-killed P. gingivalis was used to challenge the splenocytes and bone
marrow-derived macrophages. P. gingivalis DNA was isolated using re-
peated phenol-chloroform extractions as described previously (20). The
cells were stimulated with ODN 1668 (TLR9 agonist, 100 ng/l; InviVo-
gen), P. gingivalis (multiplicity of infection [MOI] of 1:100), P. gingivalis
DNA (100 ng/l), P. gingivalis lipopolysaccharide (LPS) (10 ng/l; Invi-
Vogen), Escherichia coli LPS (10 ng/l; InviVogen), and Pam3Cys (1 ng/
l; InviVogen) for 24 h. Inflammatory cytokine levels (IL-6 and TNF)
were determined in cell-free culture supernatants using ELISAs (eBiosci-
ences). Unstimulated cells were used as negative controls.
Surface staining and flow cytometry. Individual cell populations of
the splenocytes were determined in unstimulated and stimulated cells at
baseline and at 24 and 48husing flow cytometry. The following antibodies
were used: anti-mouse Ly-6G–fluorescein isothiocyanate (FITC) anti-
body (clone 1A8), anti-mouse CD3-phycoerythrin (PE) antibody (clone
145-2C11), anti-mouse Gr-1–peridinin chlorophyll protein (PerCP) an-
tibody (clone RB6-8C5), anti-mouse B220-allophycocyanin (APC) anti-
body (clone RA3-6B2), anti-mouse CD11c-APC-Cy7 antibody (clone
N418), anti-mouse F4/80-PE-Cy7 antibody (clone BM8), anti-mouse/
human CD11b-brilliant violet 711 antibody (clone M1/70), and rat anti-
mouse Ly-6C–brilliant violet 421 antibody (clone AL-21). All antibodies
were purchased from BioLegend except for the Ly-6C antibody, which
was fromBDPharmingen. Surface staining of splenocytes for flow cytom-
etrywas performedby incubating cells for 30min on ice in a 1:100 dilution
of antibody in 2% fluorescence-activated cell sorting (FACS) buffer (PBS
supplemented with 2% fetal calf serum). After being washed three times
with FACS buffer, cells were fixed in 2% paraformaldehyde (Sigma-Al-
drich). All samples were acquired on a BD LSRFortessa instrument, and
the data analyzed using FlowJo software (TreeStar). Following gating on
the viable single cell population, macrophages were defined as CD11bhi
Gr-1 F4/80, neutrophils as CD11b Gr-1 Ly-6Clo, monocytes as
CD11b Gr-1 Ly-6Chi, conventional dendritic cells as CD11b B220,
B cells as B220, and T cells as CD3.
RNA isolation and real-time PCR. Total RNA was isolated from
splenocytes using the RNeasy kit (Qiagen) and gDNA eliminator spin
columns. The amount of RNA was determined spectrophotometrically,
and the RNA quality was assessed by performing 1% agarose gel electro-
phoresis. cDNA was synthesized from 1.0 g total RNA using a high-
capacity cDNA reverse transcription kit (Applied Biosystems) according
to the manufacturer’s protocol. cDNA was kept on ice prior to gene ex-
pression analyses or stored at 20°C until use. The expression of the
receptors was determined by real-time PCR (Applied Biosystems 7500)
using specific primers (for TLR2, forward, 5=-CCT GGC CCT CTC TAC
AAA CTT-3=, and reverse, 5=-ACT GTG TAT TCG TGT GCT GGA TA-
3=, and for TLR4, forward, 5=-TGCTGCCGTTTTATCACGGA-3=, and
reverse, 5=-CTA AAC TCT GGA TGG GGT TTC C-3=; IDT, Inc.) and
SYBR greenmastermix (SaBiosciences). TheGAPDHgenewas used as an
Kim et al.
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internal control. The relative amount of each gene was calculated using
the 2CT method, where CT (CTmRNA CTGAPDH).
Western blotting. Murine splenocytes were stimulated with E. coli
LPS or Pam3Cys or left unstimulated for 24 h in 24-well plates (6 
105/well). After being washed with ice-cold PBS, the cells were collected
and lysed in 100 l of ice-cold NP-40 lysis buffer (25 mM Tris–HCl, pH
7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA, pH 8), including 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1mMNa3VO4, 1mMdithiothre-
itol (DTT), and 1 protease inhibitor cocktail (Sigma-Aldrich), by re-
peated pipetting and then homogenized twice at 50% pulse for 30 s each
time using an ultrasonic homogenizer (BioLogics, Inc., Cary, NC). The
protein concentration was determined using the bicinchoninic acid
(BCA) protein assay kit (Thermo Scientific). Cell lysates (25 g protein)
were subjected to electrophoresis on 4-to-15% Mini-Protean TGX gels
(Bio-Rad) and transferred to nitrocellulose membranes, followed by
Western blotting according to standard techniques. Briefly, the mem-
branes were incubated with primary antibody (rabbit monoclonal anti-
mouse TLR-2 antibody, 1:1,000 dilution; Cell Signaling) or anti-mouse
actin antibody (1:200 dilution; Santa Cruz Biotechnology) in 5% nonfat
dry milk–Tris-buffered saline supplemented with 0.05% Tween 20
(TBST) solution at 4°C overnight and then with Immun-Star HRP-
conjugated secondary antibody (goat anti-rabbit or goat anti-mouse
IgG, 1:3,333) in 5% nonfat dry milk–1 TBST solution at room tem-
perature for 1 h. Immunoreactive bands were visualized by using Su-
perSignal West Pico chemiluminescent substrate (Thermo Scientific)
followed by exposure to X-ray film. Densitometric analyses were per-
formed using the G:BOX Chem XX6 system and GeneTools image
analysis software (Syngene). TLR-2 levels in control samples were de-
termined as the percentages of total actin protein bands. To quantify
TLR-2 levels following stimulation, the levels of actin and TLR-2 were
normalized between samples. The TLR-2 signal was then normalized
to actin protein levels.
Statistical analysis. Data were analyzed by one-way analysis of vari-
ance (ANOVA) and theTukeymultiple-comparison test or unpaired t test
using the InStat program (GraphPad Software, San Diego, CA). A P value
of	0.05 was considered significant.
RESULTS
P. gingivalis infection. We investigated the role of TLR9 in peri-
odontal disease pathogenesis using the P. gingivalis-induced mu-
rine periodontitis model. P. gingivalis colonization, as well as P.
gingivalis-specific antibody levels in the serum, were assessed to
confirm that the mice were successfully infected with P. gingivalis.
P. gingivaliswas detected inWT andTLR9/mice at comparable
levels 2 weeks postinoculation (Fig. 1A). Moreover, there was a
significant increase in P. gingivalis-specific antibody levels in both
WT and TLR9/mice inoculated with this organism compared
to the levels in sham-infected controls (P	 0.0001) (Fig. 1B). Sera
obtained prior to inoculation had no specific antibody activity
against P. gingivalis, similar to sera from sham-infectedmice (data
not shown). No significant difference was observed between the
antibody levels of P. gingivalis-infected WT and TLR9/ mice
(Fig. 1B). Therefore, TLR9 deficiency did not significantly affectP.
gingivalis colonization or the induction of systemic antibody re-
sponses to this organism. This is important for the validity of the
bone loss study (see below), since any potential differences in bone
loss between WT and TLR9/ mice would not be attributed to
differences in P. gingivalis colonization.
FIG 1 Comparison of P. gingivalis levels within the periodontal tissues (A) and P. gingivalis-specific antibody responses in serum (B) in TLR9/ andWTmice.
Each strain was orally inoculated with P. gingivalis or vehicle only (sham). The P. gingivalis levels were determined by qPCR of the ISPg1 gene (P. gingivalis) at 2
weeks postinfection. There was no statistically significant difference in P. gingivalis levels among groups. P. gingivalis-specific antibody responses were deter-
mined at the termination of the experiment. The antibody titers in TLR9/mice andWTmice infected with P. gingivaliswere significantly higher than the titers
in the uninfected mice (P	 0.0001). The data shown are the mean results
 standard deviations (SD; n 8 mice per group) and were analyzed using either the
unpaired t test or one-factor analysis of variance (ANOVA) and the Tukey test.
TLR9-Mediated Inﬂammation in Periodontitis
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TLR9-mediated inflammation promotes P. gingivalis-in-
duced periodontal bone loss. Next, we determined the effect of
TLR9 deficiency in periodontal disease progression. The disease
phenotypewas evaluated among 4 groups ofmice, which included
sham- or P. gingivalis-infected wild-type and TLR9 knockout an-
imals. The distance from the cemento-enamel junction to the al-
veolar bone crest (CEJ-ABC distance) was measured at a total of
14 predetermined buccal sites per mouse using a microscope. The
mean CEJ-ABCmeasurement for eachmouse is shown in Fig. 2A.
To calculate bone loss, the 14-site total CEJ-ABC distance for each
mouse was subtracted from themean CEJ-ABC distance of sham-
infected mice. The results are expressed in millimeters, and nega-
tive values indicate bone loss relative to the results for sham con-
trols (Fig. 2B). Analyses of the mean CEJ-ABCmeasurements and
the change in maxillary alveolar bone levels among each group
revealed significantly increased bone loss in the P. gingivalis-in-
fectedWTmice compared to the results for the sham-infectedWT
mice (P	 0.05) (Fig. 2A and B). In contrast, P. gingivalis-infected
TLR9/mice exhibited no bone loss compared to the results for
sham-infected controls (Fig. 2A and B). Moreover, P. gingivalis-
infected WT mice exhibited significantly more bone loss than P.
gingivalis-infected TLR9/mice (P	 0.01) (Fig. 2A and B). Al-
veolar bone levels were imaged using micro-CT, which displayed
visible bone destruction in infected WT mice, while no bone loss
was observed in infected TLR9 KO mice (Fig. 2C). Collectively,
these results show for the first time that TLR9 signaling mediates
the induction of alveolar bone loss.
Lack of TLR9 signaling suppresses inflammation in gingival
tissues of P. gingivalis-infectedmice.Our results revealed signif-
icantly less bone loss in P. gingivalis-infected TLR9-deficient mice
compared to the amount of bone loss in infected WT mice. We
therefore hypothesized that TLR9 activation promotes inflamma-
tion and osteoclastogenesis. To investigate this, dissected gingival
tissues from each group of mice were processed for qPCR to de-
termine themRNA expression of inflammatorymolecules. In line
with their susceptibility to bone loss, P. gingivalis-infected WT
mice displayed significantly increased levels of expression of IL-6,
TNF, and RANKL, a key osteoclastogenic factor, compared to the
FIG 2 TLR9 KO (TLR9/) mice are resistant to P. gingivalis-instigated
periodontal bone loss. Groups of mice (WT [n 17] and TLR9/ [n 47])
were infected with P. gingivalis (Pg) or sham infected and euthanized 42 days
later. Measurements were performed in defleshed maxillae. The data are
represented as the mean results 
 SD (n  64 mice). (A) Distance (in
millimeters) between the cemento-enamel junction (CEJ) and alveolar
bone crest (ABC) in each group of animals. (B) Amount of bone change in
WT and TLR9/ mice. Negative values indicate bone loss in P. gingivalis-
inoculated mice relative to the results for vehicle-inoculated (sham) con-
trols. (C) Representative micro-CT images of maxillae from each group of
mice. *, P 	 0.05; **, P 	 0.01.
FIG 3 Inflammatory molecule expression in gingival tissues. WT and TLR9/ mice were orally inoculated with P. gingivalis or vehicle only (sham) and
euthanized 42 days later. Gingival tissues around maxillary molars were excised and processed for qPCR analyses to determine mRNA expression of TNF (A),
IL-6 (B), and RANKL (C). Results are reported as fold induction after normalization to GAPDH. The data shown are themean results
 SD (n 5 or 6mice per
group) and were analyzed using the unpaired t test. *, P	 0.05; **, P	 0.01.
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expression levels in sham-infectedWTmice (P	 0.05) (Fig. 3). In
stark contrast, no significant increase of any of the inflammatory
markers was detected in infected TLR9/ mice compared to their
levels in sham-infectedKOmice (Fig. 3). These findings confirmand
expand the bone loss data and suggest that TLR9 signaling canmod-
ulate the progression of periodontal disease through upregulation of
inflammatory and osteoclastogenic molecules in local tissues.
Lack of TLR9 signaling leads to decreased cytokine produc-
tion in splenocytes and macrophages challenged with P. gingi-
valis.Our in vivo studies demonstrated diminished inflammation
and periodontal bone loss in P. gingivalis-infected TLR9/mice.
Our subsequent experiments assessed whether cytokine responses
to bacterial challenge differed between WT and TLR9/ cells ex
vivo. Briefly, splenocytes and bone marrow-derived macrophages
from WT and TLR9/mice were challenged with heat-killed P.
gingivalis (MOI of 1:100) for 24 h, and the levels of proinflamma-
tory cytokines (IL-6 and TNF) in the cell culture supernatants
were determined. Flow cytometry analyses showed that the ex vivo
splenocyte cell populations consisted of 47.58% B cells, 38.52% T
cells, and 13.9% other cells (monocytes, macrophages, neutro-
phils, and dendritic cells) forWTmice and 50.92%B cells, 37.99%
T cells, and 11.09% other cells for TLR9/ animals at baseline.
The distribution of individual cell populations was also compara-
ble between WT and knockout groups in unstimulated and stim-
ulated cells at the termination of the experiments (data not
shown). As expected, the results of the ex vivo studies were consis-
tent with the in vivo observations and revealed significantly less
IL-6 and TNF production (P 	 0.05) in response to P. gingivalis
challenge in TLR9/ macrophages (Fig. 4A and B) and spleno-
cytes (Fig. 4C andD) than inWTcells. ODN1668 (synthetic TLR9
agonist) and P. gingivalis DNA were included as controls, and as
expected, TLR9/ cells failed to produce any of the cytokines
when challenged with ODN 1668 and bacterial DNA.
Lack of TLR9 signaling affects cytokine production in
splenocytes and macrophages challenged with TLR2 and TLR4
agonists. Physiological responses require interaction of multiple
components of the host and the microbiome, and cross talk
among different innate immune signaling pathways plays a crucial
role in determining the disease outcome (34). Therefore, the de-
velopment of effective therapeutics ideally requires careful char-
acterization of all possible interactions. Previously, we reported
that inhibition of TLR9 signaling in humanmacrophage-like cells
(THP-1) affects cytokine production in response to P. gingivalis
LPS (21). This prompted us to think of a possible interaction of
TLR9 in TLR2/TLR4-driven periodontal inflammation. Given the
evidence regarding TLR9 cooperation with TLR2 and TLR4 in
other disease models, we determined whether the immune re-
sponses vary in cells fromWT and TLR9/mice upon challenge
with TLR2 and TLR4 agonists. Splenocytes and bone marrow-
derived macrophages from WT and TLR9/ mice were chal-
lengedwith different TLR agonists (Pam3Cys for TLR2,E. coliLPS
for TLR4, P. gingivalis LPS for TLR4, andODN1668 for TLR9) for
24 h, and cytokine production was determined in cell culture su-
pernatants using ELISA. There were significantly increased levels
of both IL-6 and TNF in WT cells in response to all of the stimuli
compared to the levels in unstimulatedWT cells (Fig. 5). Accord-
ingly, TLR9/ cells also responded to each challenge except for
the ODN 1668 challenge with significantly increased cytokine
production compared to the levels in unstimulated TLR9/ cells
(Fig. 5). There were variations in the cytokine levels produced by
FIG 4 Comparison of proinflammatory cytokine production in WT versus TLR9/ macrophages (A, B) and splenocytes (C, D) in response to P. gingivalis
challenge after 24 h. The cells were stimulated with heat-killed P. gingivalis (MOI of 1:100), P. gingivalis DNA (100 ng/l), and ODN 1668 (TLR9 agonist), and
cell-free supernatants were analyzed for the presence of IL-6 and TNF using ELISA. Comparisons between the results forWT and TLR9KO cells were performed
using the unpaired student t test. The levels of IL-6 and TNF production were significantly reduced in TLR9/ macrophages (A, B) and splenocytes (C, D)
compared to the levels inWT cells. The results shown are representative of at least 3 independent experiments that were run in triplicates. The data shown are the
mean results
 SD (n 9). *, P	 0.05; ***, P	 0.001; ****, P	 0.0001.
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macrophages and splenocytes depending on each stimulus. Upon
challenge with Pam3Cys and E. coli LPS, TLR9/ macrophages
produced significantly less IL-6 than WT cells. In contrast, the
IL-6 and TNF levels were similar in KO and WT macrophages in
response to P. gingivalis and E. coli LPS and Pam3Cys (Fig. 5A and
B). TLR9/ splenocytes produced significantly less IL-6 in re-
sponse to all of the ligands (Fig. 5C). TNF production was also
significantly diminished in TLR9/ splenocytes in response to
each challenge except E. coli LPS (Fig. 5D). Our further analyses
revealed equal levels of expression of TLR2 and TLR4 in WT and
KO cells, indicating that the diminished cytokine levels in TLR9-
deficient cells were not due to altered TLR2 and TLR4 expression
(Fig. 6). The levels of TLR2 and TLR4 mRNA expression were
comparable in wild-type and TLR9-deficient cells both at baseline
and upon ligand challenge (Fig. 6A and B). Western blot analyses
also revealed equal levels of expression of TLR2 in WT and
TLR9/ cells (Fig. 6C, D, and E).We were unable to detect TLR4
expression in either cell type by Western blot analyses (data not
shown). Together, our ex vivo studies provide evidence that TLR9
modulates TLR2- and TLR4-triggered inflammation and suggest
that TLR9 signaling possibly contributes to periodontal disease
through cross talk with other innate signaling pathways also.
DISCUSSION
The oral mucosa is constantly exposed to microbes, and tissue
homeostasis requires a balance between microbial cell turnover
and host proinflammatory and anti-inflammatory responses. Dis-
ruption of this homeostatic balance by certain environmental ex-
posures (e.g., smoking, obesity, or stress), host genetic and epige-
netic defects in innate responses, or subversion of the host
response by dysbiotic microflora can lead to destructive inflam-
mation, precipitating periodontitis (35–41). Recently, TLR9 sig-
naling has emerged as a potential inflammatory pathway in peri-
odontitis pathogenesis on the basis of clinical and in vitro
investigations. Confirming the role of specific genes and cells in a
disease process requires in vivo investigations that better simulate
the physiological environment (26). The results of the current
study demonstrate that TLR9 signaling in vivo can mediate the
induction of inflammatory and osteoclastogenic cytokines (IL-6,
TNF, and RANKL), as well as bone loss, in a well-established and
validated periodontitis model (26, 27). Complementing the in
vivo results, our ex vivo studies also demonstrated diminished cy-
tokine production in TLR9/ macrophages and splenocytes in
response to P. gingivalis challenge. Taken together, therefore, our
preclinical data suggest that TLR9 activation may be involved in
the induction and/or exacerbation of periodontal disease.
Intriguingly, our findings also revealed that TLR9 deficiency
can affect the extent of inflammatory responses to TLR2 andTLR4
ligands despite similar levels of TLR2 and TLR4 expression inWT
and TLR9 KO cells. The induction levels of the cytokines studied
varied depending on the cell type being studied and the specificity
of the ligand challenge. In this regard, TLR9 activation seemed to
have a more pronounced effect on IL-6 levels than on TNF levels.
It was reported previously that P. gingivalis can activate the
MyD88-independent proinflammatory phosphatidylinositol
3-kinase (PI3K) pathway in neutrophils but not in macrophages
FIG 5 Comparison of proinflammatory cytokine production in WT and TLR9/ macrophages (A, B) and splenocytes (C, D) in response to different TLR
agonists. The cells were stimulated with ODN 1668 (TLR9 agonist; 100 ng/l), P. gingivalis LPS (TLR4 agonist; 10 ng/l), E. coli LPS (TLR4 agonist; 10 ng/l),
or Pam3Cys (TLR2 agonist; 1 ng/l) for 24 h. Cell-free supernatants were analyzed for the presence of IL-6 and TNF using ELISA. The results shown are
representative of at least 3 independent experiments that were run in triplicates. The data shown are the mean results
 SD (n 9). Comparisons betweenWT
and KO cells were performed using the unpaired Student t test. *, P	 0.05; **, P	 0.01; ***, P	 0.001; ****, P	 0.0001.
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(40), whereas P. gingivalis-induced TNF production is predomi-
nantly driven by the TLR2-MyD88 pathway inmacrophages (41).
The latter findingmay possibly explainwhy TLR9 deficiency had a
relativelymodest effect onTNFproduction as opposed to its effect
on IL-6. We also observed that TLR9/ macrophages exhibited
higher levels of IL-6 and TNF production in response to P. gingi-
valis DNA and whole bacteria than to ODN 1668. One possible
explanation for this observation is that natural microbial DNA
may have additional targets, whereas ODN 1668 may have exclu-
sive specificity for TLR9. In this regard, there are other cytoplas-
mic receptors, such as absent in melanoma 2 (AIM2) and DNA-
dependent activator of IFN regulatory factors (DAI), that can
respond to microbial DNA (42). Although it is beyond the scope
of this article, we can speculate that P. gingivalis DNA can be
engaged by other nucleic acid sensors as well. In fact, our previous
clinical studies also showed increased DAI expression in chronic
periodontitis lesions compared to its expression in healthy tissues
(14). Future studies are warranted to delineate the extent of in-
volvement of other microbial DNA sensors in periodontitis
pathogenesis.
The immune response to a particular antigen may also vary
depending on the individual cell type, the tissue-specific localiza-
tion of the antigen, and the receptors and signaling molecules
involved. Our findings also revealed that immune responses to the
same antigenic challenge vary in different cell types, e.g., macro-
phages versus splenocytes, which further supports this notion.
Macrophages are thought to play important roles in periodontal
lesions. As microbial DNA engages with TLR9 following phago-
cytosis, our current study primarily focused on an evaluation of
inflammatory responses in macrophages ex vivo. However, it is
important to note that periodontal tissues are composed of differ-
ent cell types of bothmyeloid and nonmyeloid origin and TLR9 is
expressed in multiple types of cells, including gingival keratino-
cytes, dendritic cells, and neutrophils. Additionally, our previous
study revealed increasedTLR9 expressionwithin both the connec-
tive tissue and basal epithelial layers of the diseased periodontal
FIG 6 TLR2 and TLR4 expression inWT versus TLR9/ splenocytes. The cells were stimulated with E. coli LPS (TLR4 agonist; 10 ng/l) and Pam3Cys (TLR2
agonist; 1 ng/l) for 24 h. The gene (A, B) and protein (C, D, E) expression levels in unstimulated and stimulated cells were determined using qPCR andWestern
blotting. TLR2 and TLR4mRNA expression levels were equivalent inWT and TLR9/ cells at baseline and following Pam3Cys (A) and LPS (B) challenge. The
baseline and stimulated TLR2 protein levels were also equal in WT and TLR9/ cells (C, D, E).
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tissues (14). Therefore, future studies utilizing more targeted ap-
proaches, such as cell lineage-specific conditional knockout mice,
are warranted to determine the cell types that are driving TLR9-
mediated inflammation in periodontal tissues.
The polymicrobial nature of periodontitis and the presence of
various cells forming the periodontal structures create an environ-
ment for simultaneous interaction of distinct sensors and peri-
odontal MAMPs. Hence, the activation of multiple receptors and
cross talk among intracellular signaling proteins eventually deter-
mines the periodontal disease outcome. Although ligand recogni-
tion shows specificity for each receptor, the downstream signaling
pathways activated by TLRs have some redundancy, generating
the potential for signaling cross talk. In fact, the involvement of
TLR2-mediated immune responses and their cooperation with
other innate sensing molecules, such as complement receptors, in
periodontal inflammation has been documented (43). Intrigu-
ingly, cross talk between TLR9, TLR2, and TLR4 has been re-
ported in several other disease models (44–48). For example, a
study using an in vivo model of hypersensitivity pneumonitis re-
vealed that TLR2 and TLR9 cooperated in neutrophil recruitment
and IL-17-associated cytokine production such that both neutro-
phil recruitment and cytokine production were significantly de-
creased in double-KOmice (TLR2/9/) compared to their levels
in TLR2/mice (49). TLR9 has also been reported to be critical
for the development of Th17-mediated granulomatous inflam-
mation in the lung in response to Stachybotrys chartarum sensiti-
zation (50). The study demonstrated decreased expression of sev-
eral proinflammatory cytokines, as well as IL-17 and IL-23, in
TLR9 KO cells (50). Another in vivo investigation reported signif-
icant synergy between TLR2 and TLR9 for induction of the
MyD88-dependent splenic cytokine and chemokine response to
Streptococcus pneumoniae (46). Thus, it is plausible that TLR9
communicates with other receptors and signaling pathways in the
course of periodontal inflammation as well. This notion is sup-
ported by our findings. First, our results revealed that the levels of
IL-6 and TNF were significantly reduced in TLR9/ cells chal-
lenged with TLR2 and TLR4 agonists compared to the levels of
these cytokines in wild-type cells. These results imply that im-
paired TLR9 signaling can modulate TLR2- and TLR4-mediated
immune responses, possibly communicating through down-
stream signaling pathways. However, it is also important to em-
phasize that although there were significant reductions in the cy-
tokine levels in TLR9/ cells compared to the levels in WT cells,
the cytokine levels still remained significantly high in LPS- and
FIG7 Model for TLR9-mediated periodontal inflammation. Polymicrobial challenge exposes periodontal tissues to variousMAMPs associatedwith periodontal
bacteria (e.g., LPS, fimbriae, lipoproteins, and nucleic acids, etc.), leading to activation of distinct host innate receptors, as indicated. Cross talk among different
innate sensors can determine the periodontal disease clinical outcome. Microbial DNA, which is released following phagocytosis of microbial cells, can engage
TLR9 within the endolysosomal compartment and start a cascade of signaling events that mediate inflammatory responses that contribute to periodontal tissue
destruction, either alone or possibly through communication with other innate sensors, such as TLR2 and TLR4. MyD88, myeloid differentiation primary
response 88; MAPK, mitogen-activated protein kinase; AP-1, activator protein 1; NF-B, nuclear factor kappa B; IRF-7, interferon regulatory factor 7).
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Pam3Cys-treated TLR9/ cells compared to the levels in un-
stimulated cells. Second, although TLR2 has been conclusively
implicated in P. gingivalis-induced periodontal bone loss (2, 40,
41), TLR9/ mice were completely resistant to P. gingivalis-in-
duced bone loss in this study. Together, these findings suggest that
TLR9 possibly interacts with and amplifies TLR2-mediated in-
flammation. The potential role of TLR9-mediated inflammation
in periodontal disease pathogenesis is summarized in the model
shown in Fig. 7. Our observations highlight a critical aspect of
microbial DNA sensing in relation to other signaling pathways of
importance for periodontitis and warrant further investigations
utilizing in vivomodels and transgenic animals to fully character-
ize the extent of communication andmolecular pathways between
TLR9 and other innate sensors in periodontitis pathogenesis.
Conventional periodontal therapy is generally not effective to
control the persistent forms of periodontal disease, and current
research efforts focus on identifying alternative or adjunctive ther-
apeutic options to prevent the progression of periodontal disease
in local tissues and block its adverse effects on systemic tissues (51,
52). It is now well documented that communication among dif-
ferent receptors and downstream signaling molecules is impor-
tant in the progression of periodontal inflammation. Therefore,
controlling periodontal inflammation and pathological bone loss
will require better understanding of the signaling pathways acti-
vated by multiple receptors. To our knowledge, this is the first in
vivo demonstration that a nucleic acid sensor, TLR9, can mediate
destructive periodontal inflammation and can therefore be con-
sidered a potential therapeutic target for periodontal disease.
Small-molecule inhibitors of TLR9 signaling are already commer-
cially available and are being evaluated for the treatment of vari-
ous inflammatory disorders (53–55). Our findings provide for the
first time a strong mechanistic rationale for investigating the effi-
cacy of TLR9 small-molecule inhibitors in controlling periodon-
titis in a preclinical setting and, ultimately, in future clinical trials.
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